Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients ...
Interaction Design Foundation22 小时
8 Essential Writing Tips for a Clear and Confident UX/UI Design Portfolio
Writing excellence is eight practical tips away! Use proven writing tools like the inverted pyramid and the ladder of ...
Plus Therapeutics Inc.: Plus Therapeutics Reports Third Quarter 2024 Financial Results and ...
Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReS ...